A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 62
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : bDMARD
Long Form : biologic DMARD
No. Year Title Co-occurring Abbreviation
2022 Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. DMARD, JAKi, OMA, RA, TNFi
2022 Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study. aHR, CI, DMARD, HZ, RA, tsDMARD
2022 Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study. DMARDs, JIA
2022 Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany. IR, JAKi, ts
2022 Single-centre experience of refractory rheumatoid arthritis. IQR, RefRA, TTs
2022 Upadacitinib for the Treatment of Rheumatoid Arthritis: An Extensive Review. csDMARDs, JAK, RA
2021 Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs. BASDAI, csDMARD, DMARDs, PsA, PsAQoL, QoL
2021 Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach. CR, DMARD, JIA, sDMARD
2021 Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA. cJADAS, TNFi
10  2021 Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study. csDMARD, HAQ-DI, IR, LDA, NRI, SDAI
11  2021 Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020. ---
12  2021 LOOP, a cross-sectional, observational study investigating the clinical specialty setting as a determinant of disease management in psoriatic arthritis: Subgroup analysis results from Japan. csDMARD, PsA
13  2021 MTX optimization or adding bDMARD equally improve disease activity in rheumatoid arthritis: results from the prospective study STRATEGE. ---
14  2021 Real-World Data from a Multi-Center Study: Insights to Psoriatic Arthritis Care. csDMARDs, IRs
15  2021 Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry. ASDASs, axSpA, CII, MI, nr-axSpA, r-axSpA
16  2021 Summarizing current refractory disease definitions in rheumatoid arthritis and polyarticular juvenile idiopathic arthritis: systematic review. polyJIA
17  2021 The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States. csDMARD, DMARD, DMARD, MACE, P100PY, RA, VTE
18  2020 Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis. csDMARD, JIA, MTX, pJIA, s.c
19  2020 Angiogenic cytokines can reflect the synovitis severity and treatment response to biologics in rheumatoid arthritis. cDMARD, CRP, DAS28, ESR, PlGF, RA, US
20  2020 Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial. AEs, CDAI, csDMARDs, RA
21  2020 High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study. DMARD, PsA, SPAIG
22  2020 Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: aNordic population-based cohort study. ADA, CZP, ETN, GOL, IFX
23  2020 Response to interleukin-6 receptor antagonists in patients with rheumatoid arthritis is independent of the number of prior used TNF inhibitors: A systematic review and metaanalysis. RA, RCTs, SAR, TCZ, TNFis
24  2020 Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7years. ACR, AESIs, DMARD, LTE, RA, ROW, TB
25  2020 Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy. PROMs, RA, RAID
26  2020 Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate. ADA, DMARDs, ETN, MTX, RA
27  2019 Adherence in rheumatoid arthritis patients assessed with a validated Italian version of the 5-item Compliance Questionnaire for Rheumatology. csDMARD, HAs, I-CQR5, LAs, PCM, RA
28  2019 Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs: Results From a Real-World Study. ACPA, cDMARD, DMARDs, HR, RA, RF
29  2019 Cervical screening uptake and rates of cervical dysplasia in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. HGCD and LGCD
30  2019 Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States. nr-axSpA
31  2019 Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis. DMARD, JIA, MTX
32  2019 Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results. AE, csDMARD, MTX, OBRI, RA
33  2019 Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis in the United States: A Multicenter Observational Study. csDMARD, PsA
34  2019 Large-vessel Vasculitis Affecting the Aorta and its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature. csDMARD, LVV, RP
35  2019 Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA. DMARD, RA, RAID, TSQM
36  2019 Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system. ---
37  2019 Predictive value of ex-vivo drug-inhibited cytokine production for clinical response to biologic DMARD therapy in rheumatoid arthritis. AUCs, RA
38  2018 Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study. ---
39  2018 Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry. csDMARDs, NOR-DMARD
40  2018 Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. CDAI, DMARDs, LDA, RA, TCZ, TCZMONO, TNF, TNFi mono
41  2018 How to treat patients with rheumatoid arthritis when methotrexate has failed? The use of a multiple propensity score to adjust for confounding by indication in observational studies. DAS, DMARD, PS, RA
42  2018 In early arthritis patients, high HAQ at baseline and DAS28 at three months predict suboptimal outcomes at two years: a retrospective cohort study. EAC, RA
43  2018 Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1. AE, cDMARDs, HAQ-DI, PsA
44  2018 Long-term persistence with rituximab in patients with rheumatoid arthritis. RTX
45  2017 Abatacept: A Review in Rheumatoid Arthritis. cDMARD, RA, s.c
46  2017 Biologic Disease-modifying antirheumatic drug attributes in the first lines of treatment of rheumatoid arthritis. 2015 ACORDAR project. RA
47  2017 Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort. cDAPSA, csDMARD, DAPSA, LDA, MDA, PASDAS, PsA
48  2017 Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study. CDAI, csDMARD, NORD-STAR, RA
49  2017 Non-persistence and non-adherence to MTX therapy in patients with rheumatoid arthritis: a retrospective cohort study based on German RA patients. MPR, MTX, NA, NP, RA, sDMARD
50  2017 Tenosynovitis in rheumatoid arthritis patients on biologic treatment: involvement and sensitivity to change compared to joint inflammation. ECU, GS, PD, SRMs, TP, US
51  2017 Treatment patterns in rheumatoid arthritis after discontinuation of methotrexate: data from the Ontario Best Practices Research Initiative (OBRI). csDMARD, MTX, OBRI, RA
52  2017 Use of Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in US Veterans: Effect of Specialty Care and Geographic Distance. DMARD, IA, sDMARD, VA
53  2016 Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: Meta-analysis of randomized controlled trials. sDMARD, SHS
54  2016 Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. cs
55  2016 Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study. DMARDs, RA, RR
56  2016 Ultrasound Doppler but not temporal summation of pain predicts DAS28 response in rheumatoid arthritis: a prospective cohort study. TS
57  2015 Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. csDMARDs, DANBIO
58  2015 Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry. CDAI
59  2015 The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. SmPC
60  2014 The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. EULAR
61  2013 Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritis. CDAI, DMARD, MV, PS, RA
62  2013 Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010. DAS28, DMARDs, MTX, NOR-DMARD, RA